OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2017.7005 OL-0-0-7005 Articles A correlation analysis between tumor imaging changes and p-AKT and HSP70 expression in tumor cells after osteosarcoma chemotherapy JiFeng 1 LvRan 2 ZhaoTing 1 Department of Radiology, Liaocheng People's Hospital, Liaocheng, Shandong 252000, P.R. China Department of Medical Oncology, Liaocheng Tumor Hospital, Liaocheng, Shandong 252000, P.R. China Correspondence to: Dr Ting Zhao, Department of Radiology, Liaocheng People's Hospital, 67 Dongchangxi Road, Liaocheng, Shandong 252000, P.R. China, E-mail: drtingzhao@163.com 12 2017 20 09 2017 14 6 6749 6753 01062017 11092017 Copyright: © Ji et al. 2017 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

This study sought to investigate osteosarcoma property changes after neoadjuvant chemotherapy and to analyze any correlation between changes with phospho-AKT (p-AKT) and heat shock protein 70 (HSP70) expression in osteosarcoma cells. Thirty patients with osteosarcoma treated at Liaocheng People's Hospital between January and October, 2016 were given an imaging examination before and after neoadjuvant chemotherapy to examine osteosarcoma tumor properties, with images scored. Immunohistochemistry was used to determine p-AKT and HSP70 expression levels, as well as tumor cell necrosis rate (TCNR), in specimens obtained before and after chemotherapy. The correlation between the imaging changes of osteosarcoma after chemotherapy and the expressions of p-AKT and HSP70 in tumor cells. Compared with pre-chemotherapy, the imaging scores of the 30 patients significantly increased after chemotherapy (P<0.05). The radiographic score of the TCNR ≥90% group was 11.3±0.5, which was significantly higher than that of the TCNR <90% group (8.7±0.3, P<0.05). p-AKT expression in osteosarcoma cells was found in 13.3% of samples (4/30 cases) after chemotherapy, which was significantly lower than prior to chemotherapy (73.3%, 22/30 cases, P<0.05). After chemotherapy, HSP70 expression in osteosarcoma cells was found in 6.7% of samples (2/30 cases), which was significantly lower than prior to chemotherapy (83.3%, 25/30 cases, P<0.05). p-AKT and HSP70 expression levels were found to be correlated with TCNR after chemotherapy (P<0.05). After chemotherapy, p-AKT and HSP70 expression levels demonstrated a positive correlation with TCNR. Tumor property changes, as uncovered by imaging, were significantly inversely correlated with tumor cell p-AKT and HSP70 expression after chemotherapy. Therefore, osteosarcoma properties, as determined through X-ray imaging, were closely related to p-AKT and HSP70 expression in osteosarcoma cells after neoadjuvant chemotherapy. The effect of chemotherapy can be evaluated by observing the above examination results.

 osteosarcoma imaging changes tumor cells phospho-AKT heat shock protein 70 Introduction

Osteosarcoma grows quickly and is more likely to develop pulmonary metastasis during the early phase. Moreover, patients are prone to multidrug resistance, so there is a certain degree of difficulty present regarding clinical treatment (1). Although chemotherapy and surgery techniques have made great progress in recent years, the 5-year survival rate of osteosarcoma patients has not significantly improved (2,3). For this reason, it is necessary to actively explore new potentially effective treatments for osteosarcoma. Neoadjuvant chemotherapy is a new strategy for tumor treatment developed in recent years. Phospho-AKT (p-AKT) and heat shock protein 70 (HSP70) are important proteins which actively participate in the pathogenesis and development of various diseases such as liver and gastric cancers. At present, there is no data on the relationship between p-AKT and HSP70 protein expression levels in osteosarcoma cells and physical tumor properties after neoadjuvant chemotherapy. The aim of this study was to investigate visible changes to osteosarcomas after neoadjuvant chemotherapy and to determine whether any correlation between these changes and osteosarcoma cell p-AKT and HSP70 expression exists, in order to provide a theoretical basis for the clinical treatment of osteosarcoma.

 Materials and methods <sec> <title>General patient information

Thirty patients with osteosarcoma admitted to Liaocheng People's Hospital between January and October, 2016 were selected as subjects. Inclusion criteria in the study were as follows: i) patients with osteosarcoma confirmed by pathological examination (4); ii) patients who received the same new auxiliary chemotherapy regimen before operation; iii) patients and/or guardians who signed informed consent. Exclusion criteria were as follows: i) patients who presented osteosarcoma in combination with other cancers; ii) patients suffering from heart, brain, and other vital organ diseases; iii) patients who were non-compliant with treatment. The thirty subjects selected (18 males and 12 females, aged 18–37 years, mean age 23.4±3.5 years) presented 14 cases of osteosarcoma in the distal femur, 7 cases in the upper tibia, 5 cases in the proximal femur, 2 cases in the iliac crest, and 2 cases in the proximal humerus. Treatment regimen was as follows: patients received two courses of neoadjuvant chemotherapy MMIA (6 weeks) before operation, rested for 14 days prior to surgery, and then resumed chemotherapy after operation. The study was approved by the Ethics Committee of Liaocheng People's Hospital.

 Imaging examinations before and after chemotherapy

All patients received conventional X-ray examinations before chemotherapy and after 2 courses of chemotherapy.

 Osteosarcoma imaging score

The osteosarcoma imaging was scored as outlined in Table I, and the imaging features of the patients before and after chemotherapy were quantified according to the criteria presented in Table I.

 Pathological examinations and determination of p-AKT and HSP70 expression Hematoxylin and eosin (H&E) and immunohistochemical staining

Needle biopsies were obtained from all patients before chemotherapy, embedded in wax blocks, and collected. Tumor specimens were obtained from all patients during the course of the operation after chemotherapy were also embedded in wax blocks. All blocks were sectioned and subjected to H&E, p-AKT and HSP70 immunohistochemistry staining. p-AKT, HSP70 and other relevant immunohistochemical kits were purchased from Shanghai Fusheng Industrial Co., Ltd. (Shanghai, China). Sections known to present positive-expression positive controls and phosphate-buffered saline (PBS) negative controls were generated simultaneously.

 Immunohistochemical staining evaluation criteria

Ten casual fields of view were observed under microscopy, with yellow or brown particles in the nuclei or cytoplasm with clear backgrounds being considered as positive staining. In addition, samples showing positive staining were divided into strong staining (>95% positive cells), moderate staining (51–95% positive cells), weak staining (2–50% positive cells), and absence of expression (<2% positive cells) categories (5). In this study, weak staining and absence of expression were interpreted as negative expression, and strong staining and moderate staining as positive expression.

 Evaluation of tumor cell necrosis rate (TCNR)

TCNR was calculated in accordance with previously published literature (6) for all patients with preoperative chemotherapy.

 Statistical analysis

Statistical analysis was performed using SPSS 20.0 (IBM, Armonk, NY, USA). The data were expressed as mean ± SD. The enumeration data were analyzed by paired samples t-tests, and measurement data were compared using χ2 tests. The correlation analyses between p-AKT and HSP70 expression levels, TCNR, and image scoring were performed with χ2 tests. A P<0.05 was considered as statistically significant.

 Results <sec> <title>Changes in osteosarcoma characteristics before and after chemotherapy

In this study, osteogenic changes were observed in 20 patients, osteoporosis in 6 cases, and a mixture of the two in 4 cases before chemotherapy. All patients exhibited typical osteosarcoma osteolytic or sclerotic changes, with the tumor border being unclear with cortical bone damage. An example of visible changes to distal femoral osteosarcoma properties before and after chemotherapy is shown in Fig. 1. An example of visible changes to iliac osteosarcoma properties are shown in Fig. 2.

Imaging showed a significant increase in radiographic score after chemotherapy (P<0.05) compared with before chemotherapy (Table II).

 The relationship between imaging score changes and TCNR after chemotherapy

A TCNR ≥90% indicated good patient prognosis (7). Patients were divided into TCNR ≥90% (n=21) and TCNR <90% groups (n=9), with statistical analysis showing that the average imaging score of the TCNR ≥90% group was 11.3±0.5 points, which was significantly higher than that of the TCNR <90% group (8.7±0.3, P<0.05) (Fig. 3).

 The relationship between the expression of p-AKT and HSP70 in tumor cells and TCNR after chemotherapy

Positive staining for p-AKT and HSP70 proteins manifested as purple particles in the cytoplasm (Figs. 4 and 5). The positive expression rate of p-AKT in osteosarcoma cells was 13.3% (4 of 30 cases), which was significantly lower than the 73.3% found before chemotherapy (22 of 30 cases, p<0.05). After chemotherapy, the positive expression rate of HSP70 in osteosarcoma cells was 6.7% (2 of 30 cases), which was significantly lower than the 83.3% found before chemotherapy (25 of 30 cases, P<0.05) (Table III).

The expression of p-AKT and HSP70 was inversely correlated with TCNR after chemotherapy (P<0.05). The lower the expression of p-AKT and HSP70, the higher the patient TCNR value (Table IV).

 Relationship between imaging score and p-AKT and HSP70 expression after chemotherapy

Based on previous comprehensive clinical practice, a postoperative radiographic score ≥9 points was considered as effective chemotherapy, on the contrary, a score of <9 points was considered ineffective (8). Imaging score was inversely correlated with the expression of p-AKT and HSP70 in tumor cells after chemotherapy. The higher the imaging score, the lower the expression rates of p-AKT and HSP70 (Table V).

 Discussion

Neoadjuvant chemotherapy improves 5-year survival rate for osteosarcoma (9,10). After patients with osteosarcoma receive chemotherapy, tumor cells undergo necrosis, tumor tissue is directly absorbed by the body, and the gaps left are replaced by new bone (11–13), leading to increased complexity with regards to imaging results after osteosarcoma chemotherapy. The occurrence and development of osteosarcoma is closely related to cellular molecular expression levels. Moreover, changes at the molecular level are related to morphological changes which can be detected by imaging (14–17).

This study showed that typical osteosarcoma osteolytic or sclerotic changes combined with cortical bone damage occurred in all 30 patients after chemotherapy, which was consistent with previous findings (18). These changes may be related to alterations in osteosarcoma pathogenesis. After scoring patient images, we found that the imaging scores of all 30 patients significantly increased after chemotherapy (P<0.05). The radiographic score of the TCNR ≥90% group was significantly higher than that of the TCNR <90% group (P<0.05), suggesting that imaging score was positively correlated with TCNR, and accordingly, with improved patient prognosis. Therefore, imaging-detected characteristic changes can be used to predict patient chemotherapy effectiveness, thus providing a theoretical basis for clinical treatment (19).

AKT belongs to a class of important proteins in the PI3K/AKT signaling pathway, and AKT activation is dependent on the activation of upstream PI3K. p-AKT is the activated form of AKT (20). Previous data showed (21) that abnormal expression of p-AKT was found in laryngeal squamous cell carcinoma, gastric cancer, and other cancers. Heat shock proteins are stress proteins which regulate the activity and physiological function of a wide variety of proteins. HSP70 is an important member of the heat shock protein family (22). A previous study suggested (23) that HSP70 was abnormally expressed in cervical cancer, nasopharyngeal carcinoma, colorectal, and other cancers, and involved in the occurrence and development of cancers.

This study showed that the positive expression rate of p-AKT in osteosarcoma cells was 13.3% (4 of 30 cases) after chemotherapy, which was significantly lower than the 73.3% found before chemotherapy (22 of 30 cases, P<0.05). The positive expression rate of HSP70 in osteosarcoma cells was 6.7% (2 of 30 cases) after chemotherapy, which was significantly lower than the 83.3% found before chemotherapy (25 of 30 cases, P<0.05), suggesting that neoadjuvant chemotherapy drugs could effectively inhibit the proliferation of osteosarcoma cells. We also found that the expressions of p-AKT and HSP70 were correlated with TCNR after chemotherapy (P<0.05). The lower the expression rates of p-AKT and HSP70 were, the higher the TCNR was, suggesting that the expression of p-AKT and HSP70 in osteosarcoma cells after neoadjuvant chemotherapy could be used to predict the efficacy of neoadjuvant chemotherapy. In addition, imaging scores were significantly correlated with the expression rates of p-AKT and HSP70 in tumor cells. The higher the imaging score was, the lower the expression rates of p-AKT and HSP70 were, which implied that image analysis after neoadjuvant chemotherapy could be used to posit the expressions of p-AKT and HSP70 in patient tumor cells, and thus could be used to predict and evaluate the efficacy of neoadjuvant chemotherapy.

In conclusion, osteosarcoma characteristics, as detected by imaging, after neoadjuvant chemotherapy were closely related to the expressions of p-AKT and HSP70 in osteosarcoma cells. The effect of chemotherapy can be evaluated by observing the above examination results.

 References LauxCJBerzaczyGWeberMLangSDominkusMWindhagerRNöbauer-HuhmannIMFunovicsPTTumour response of osteosarcoma to neoadjuvant chemotherapy evaluated by magnetic resonance imaging as prognostic factor for outcomeInt Orthop3997104201510.1007/s00264-014-2606-525432323 KuboTFurutaTJohanMPAdachiNOchiMPercent slope analysis of dynamic magnetic resonance imaging for assessment of chemotherapy response of osteosarcoma or Ewing sarcoma: Systematic review and meta-analysisSkeletal Radiol4512351242201610.1007/s00256-016-2410-y27229874 LiHLiXYBuJXiaoTHow to explain the role of magnetic resonance imaging on evaluating tumour response of osteosarcoma to neoadjuvant chemotherapy?Int Orthop3910311032201510.1007/s00264-015-2717-725754228 JiWPHeNBInvestigation on the DNA repaired gene polymorphisms and response to chemotherapy and overall survival of osteosarcomaInt J Clin Exp Pathol8894899201525755792 HagleitnerMMCoenenMJGelderblomHMakkinjeRRVosHIde BontESvan der GraafWTSchreuderHWFluckeUvan LeeuwenFNA first step towards personalized medicine in osteosarcoma: Pharmacogenetics as predictive marker of outcome after chemotherapy based treatmentClin Cancer Res2134363441201510.1158/1078-0432.CCR-14-263825829401 SarmanHBayramRBenekSBAnticancer drugs with chemotherapeutic interactions with thymoquinone in osteosarcoma cellsEur Rev Med Pharmacol Sci2012631270201627097945 LiSSunWWangHZuoDHuaYCaiZResearch progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversalTumour Biol3613291338201510.1007/s13277-015-3181-025666750 WangXZhengHShouTTangCMiaoKWangPEffectiveness of multi-drug regimen chemotherapy treatment in osteosarcoma patients: A network meta-analysis of randomized controlled trialsJ Orthop Surg Res1252201710.1186/s13018-017-0544-928356114 ZhuXZMeiJEffect and mechanism analysis of siRNA in inhibiting VEGF and its anti-angiogenesis effects in human osteosarcoma bearing ratsEur Rev Med Pharmacol Sci1943624370201526636524 AhnJHChoWHLeeJAKimDHSeoJHLimJSBone mineral density change during adjuvant chemotherapy in pediatric osteosarcomaAnn Pediatr Endocrinol Metab20150154201510.6065/apem.2015.20.3.15026512351 ByunBHKimSHLimSMLimIKongCBSongWSChoWHJeonDGLeeSYKohJSPrediction of response to neoadjuvant chemotherapy in osteosarcoma using dual-phase (18)F-FDG PET/CTEur Radiol2520152024201510.1007/s00330-015-3609-325680716 1ChangKJKongCBChoWHJeonDGLeeSYLimILimSMUsefulness of increased 18F-FDG uptake for detecting local recurrence in patients with extremity osteosarcoma treated with surgical resection and endoprosthetic replacementSkeletal Radiol44529537201510.1007/s00256-014-2063-725431093 AvrilPLe NailLRBrennanMÁRossetPDe PinieuxGLayrollePHeymannDPerrotPTrichetVMesenchymal stem cells increase proliferation but do not change quiescent state of osteosarcoma cells: Potential implications according to the tumor resection statusJ Bone Oncol5514201510.1016/j.jbo.2015.11.00226998421 CaiSZhangTZhangDQiuGLiuYVolume-sensitive chloride channels are involved in cisplatin treatment of osteosarcomaMol Med Rep1124652470201510.3892/mmr.2014.306825503821 GuoJGlassJOMcCarvilleMBShulkinBLDaryaniVMStewartCFWuJMaoSDwekJRFayadLMAssessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRIBr J Cancer11312821288201510.1038/bjc.2015.35126461056 XiaoXWangWZhangHGaoPFanBHuangCFuJChenGShiLZhuHIndividualized chemotherapy for osteosarcoma and identification of gene mutations in osteosarcomaTumour Biol3624272435201510.1007/s13277-014-2853-525431261 LeeJAJeonDGChoWHSongWSYoonHSParkHJParkBKChoiHSAhnHSLeeJWHigher gemcitabine dose was associated with better outcome of osteosarcoma patients receiving gemcitabine-docetaxel chemotherapyPediatr Blood Cancer6315521556201610.1002/pbc.2605827197055 KatagiriHSugiyamaHTakahashiMMurataHWasaJHosakaSMiyagiMOsteosarcoma of the pelvis treated successfully with repetitive intra-arterial chemotherapy and radiation therapy: A report of a case with a 21-year follow-upJ Orthop Sci20568573201510.1007/s00776-013-0511-124357190 KleinermanEMaximum benefit of chemotherapy for osteosarcoma achieved-what are the next steps?Lancet Oncol1713401342201610.1016/S1470-2045(16)30270-427569441 FangXJiangYFengLChenHZhenCDingMWangXBlockade of PI3K/AKT pathway enhances sensitivity of Raji cells to chemotherapy through down-regulation of HSP70Cancer Cell Int1348201310.1186/1475-2867-13-4823706027 ChatterjeeMAndrulisMStühmerTMüllerEHofmannCSteinbrunnTHeimbergerTSchraudHKressmannSEinseleHThe PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myelomaHaematologica9811321141201310.3324/haematol.2012.06617523065523 BoonEvan der GraafWTGelderblomHTesselaarMEvan EsRJOostingSFde BreeRvan MeertenEHoebenASmeeleLEImpact of chemotherapy on the outcome of osteosarcoma of the head and neck in adultsHead Neck39140146201710.1002/hed.2455627507299 PanTLiXXieWJankovicJLeWValproic acid-mediated Hsp70 induction and anti-apoptotic neuroprotection in SH-SY5Y cellsFEBS Lett57967166720200510.1016/j.febslet.2005.10.06716313906

Cortical bone damage. Distal femoral osteosarcoma imaging before and after chemotherapy (A) Mixed bone destruction with periosteal reaction, soft tissue swelling, and blurred boundaries before chemotherapy. (B) Significant calcification and ossification in distal femoral osteosarcoma lesions with clear boundaries and free of soft tissue swelling after chemotherapy.

Iliac osteosarcoma imaging before and after chemotherapy (A) Osteolytic destruction with unclear boundaries and local cortical bone fracture before chemotherapy. (B) Clear tumor boundaries, local hardening, and increase of bone fracture healing and continuity were observed in iliac osteosarcoma after chemotherapy.

The relationship between imaging score changes and tumor cell necrosis rate (TCNR) after chemotherapy. The imaging score of patients in the TCNR ≥90% group was significantly higher than those in the TCNR <90% group (**P<0.05).

p-AKT expression in osteosarcoma cells detected by immunohistochemistry. (A) Positive expression of p-AKT in osteosarcoma cells. B) Negative expression of p-AKT in osteosarcoma cells.

Heat shock protein 70 (HSP70) expression in osteosarcoma cells detected by immunohistochemistry. (A) Positive expression of HSP70 in osteosarcoma cells. (B) Negative expression of HSP70 in osteosarcoma cells.

Criteria for image scoring of osteosarcoma patients.

Imaging characteristic 0 points 1 point 2 points
Bone calcification None Partial Complete
Tumor boundaries Not clear Clear Obviously clear
Bone shell formation None Partially formed Completely repaired
Osteolytic distruction area Obvious Partially present None or completely repaired
Pathological fractures Clearly present Callus formation in broken ending Healing or no pathological fracture
Periosteal reaction Obvious Less None
Soft tissue mass Obvious Less None

Imaging scores for all 30 patients before and after chemotherapy.

Patient number
Time-points 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
Before chemotherapy 4 4 7 5 6 8 7 6 7 6 4 5 5 6 7 8 5 7 8 7 6 6 6 4 4 5 5 7 8 7
After chemotherapy 8 7 9 10 11 12 10 9 11 10 8 8 7 12 10 11 8 11 12 10 9 9 10 8 8 9 8 10 12 11

Expression of p-AKT and HSP70 in osteosarcoma before and after chemotherapy.

p-AKT HSP70
Time-points n (cases) Positive Negative Positive Negative
Before chemotherapy 30 22   8 25   5
After chemotherapy 30   4 26   2 28
χ2 8.425 9.107
P-value <0.05 <0.05

HSP70, heat shock protein 70.

The relationship between expression of p-AKT and HSP70 and TCNR after chemotherapy.

p-AKT expression HSP70 expression
TCNR Positive Negative Positive Negative
≥90% 2 19 1 18
<90% 2   7 1 10
χ2 6.128 7.603
P-value <0.05 <0.05

TCNR, tumor cell necrosis rate; HSP70, heat shock protein 70.

Patient imaging score and expression of p-AKT and HSP70 after chemotherapy.

p-AKT expression HSP70 expression
Score Positive Negative Positive Negative
≥9 points 2 19 1 18
<9 points 2   7 1 10
χ2 6.128 7.603
P-value <0.05 <0.05

HSP70, heat shock protein 70.